Dr. Herbst on Immune Resistance in Lung Cancer

Video

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses mechanisms of immune resistance for patients with lung cancer.

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, at Yale Cancer Center, Smilow Cancer Hospital, discusses mechanisms of immune resistance for patients with lung cancer.

Only about 15% to 20% of patients with lung cancer derive significant benefit from immunotherapy, and there are several reasons why patients develop resistance to this treatment approach, Herbst says. The main reason is that they have “cold” tumors—their tumors are not inflamed and are without T cells.

For those 50% to 60% of patients, researchers need to find ways to bring immune cells into the tumor. Herbst suggests T cells can be attracted with cytokines through the use of biospecific antibodies or other agents can be used to modulate the tumor microenvironment to make it more favorable.

Additionally, there are some tumors that do not use PD-L1 as the primary checkpoint. If researchers can gain a better understanding of other checkpoints that may be involved, they could potentially use other agents such as TIM-3 or LAG-3 to improve response.

Herbst notes that there are still some patients whose tumors have all the favorable qualities—such as T cells and PD-L1 expression—yet they still do not respond to immunotherapy. While immunotherapy has changed the way thoracic oncologists treat lung cancer, many questions remain in this space.

Related Videos
Arya Amini, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania